US 11,739,064 B2
HDAC inhibitors and therapeutic methods using the same
Alan Kozikowski, Chicago, IL (US); and Irina Gaisina, Berwyn, IL (US)
Assigned to THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
Filed by THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
Filed on Nov. 16, 2020, as Appl. No. 17/99,360.
Application 17/099,360 is a division of application No. 15/756,086, granted, now 10,836,733, previously published as PCT/US2016/049556, filed on Aug. 31, 2016.
Claims priority of provisional application 62/252,064, filed on Nov. 6, 2015.
Claims priority of provisional application 62/213,747, filed on Sep. 3, 2015.
Prior Publication US 2021/0139438 A1, May 13, 2021
Int. Cl. A61K 31/4155 (2006.01); C07D 261/10 (2006.01); A61K 45/06 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); A61K 31/422 (2006.01); C07D 261/18 (2006.01); A61K 31/42 (2006.01); A61K 31/427 (2006.01); A61P 35/00 (2006.01)
CPC C07D 261/10 (2013.01) [A61K 31/4155 (2013.01); A61K 31/42 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 261/18 (2013.01); C07D 413/06 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); Y02A 50/30 (2018.01)] 16 Claims
OG exemplary drawing
 
1. A method of inhibiting HDAC, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula:
(Ia):

OG Complex Work Unit Chemistry
wherein A is selected from the group consisting of
—C(═O)NHheteroaryl, —NHC(═O)heteroaryl, aryl, heteroaryl, and

OG Complex Work Unit Chemistry
 wherein B and C are, independently, aryl or heterocyclyl and n is 2 or 3;
or a pharmaceutically acceptable salt thereof; or
(Ib):

OG Complex Work Unit Chemistry
wherein A is selected from the group consisting
of, —NHC(═O)alkyl, —NHC(═O)cycloalkyl, —NHC(═O)heteroaryl, aryl, and heteroaryl; n is 0 or 1;
and p is 0 or 1; or a pharmaceutically acceptable salt thereof.